Bendroflumethiazide

Sold as Naturetin-2.5, Naturetin-5, Naturetin-10. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Bendroflumethiazide (sold as Naturetin-2.5, Naturetin-5, Naturetin-10), first approved Dec 7, 1959, with 0 new uses approved and 0 published complete response letters.

First approved: Dec 7, 1959
Applications: 1
New uses approved: 0
Complete response letters: 0

Clinical Trials

2 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Mechanisms of Diuretic Resistance in Heart Failure, Aim 3Heart Failure, Diuretic Resistance · Yale University	Phase 1	Recruiting	Jan 17, 2024
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2Heart Failure · Yale University	Phase 1	Recruiting	Mar 3, 2023

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 7, 1959	Naturetin-2.5, Naturetin-5NDA 12164 · New dosage form	Apothecon	15	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA